Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus and Metronomic Chemotherapy in Pediatric Relapsed/Refractory Solid and CNS Tumors
NCT02574728Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- Jun 2015
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in solid tumor and central nervous system tumor, sponsored by Emory University. Primary endpoints: Radiographic response to treatment for solid tumors up to 2 years and Radiographic response to treatment for central nervous system (CNS) tumors up to 2 years. Started Jun 2015; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
solid tumorcentral nervous system tumor
Beyond the preview
Go deeper on NCT02574728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574728.